Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 1023-1029

  Chew, H K ^a   Somlo, G ^b   Mack, P C ^a   Gitlitz, B ^c   Gandour edwards, R ^a   Christensen, S ^a   Linden, H ^d   Solis, L J ^a   Yang, X ^a   Davies, A M ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e OSI Pharmaceuticals   (United States)

Author keywords

EGFR (epidermal growth factor receptor); HER2; Lapatinib; PTEN; Vinorelbine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; NAVELBINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; BONE PAIN; BRAIN ISCHEMIA; BREAST CANCER; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SOLID TUMOR; SYNDROME DELINEATION; THROMBOCYTOPENIA; THYROID PAPILLARY CARCINOMA;

EID: 84859506862     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr328     Document Type: Article

References (38)

1. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19(56): 6550-6565.
2. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3): 719-726.
3. Gomez HL, Doval DC, Chavez MA et al. Efficacy and safety of lapatinib as firstline therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008; 26(18): 2999-3005.
4. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22(16): 3238-3247.
5. Giaccone G, Gallegos Ruiz M, Le Chevalier T et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006; 12(20 Pt 1): 6049-6055.
6. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361(10): 947-957.
7. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357(20): 2040-2048.
8. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1673-1684.
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659-1672.
10. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783-792.
11. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355(26): 2733-2743.
12. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376(9742): 687-697.
13. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl JMed 2009; 360(14): 1408-1417.
14. Venook A, Niedzwiecki D, Hollis D et al. Phase III study of FOLFIRI or FOLFOX 6 cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum: CALGB 80203 preliminary results. Proc Am Soc Clin Oncol 2006; 24 (18S) (Abstr 3509).
15. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22(5): 777-784.
16. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22(5): 785-794.
17. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23(25): 5892-5899.
18. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25(12): 1545-1552.
19. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-2139.
20. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101(36): 13306-13311.
21. Davies AM, Ho C, Lara Jr PN et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-smallcell lung cancer. Clin Lung Cancer 2006; 7(6): 385-388.
22. Tracy S, Mukohara T, Hansen M et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 64(20): 7241-7244.
23. Mahaffey CM, Davies AM, Lara Jr PN et al. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer 2007; 8(9): 548-553.
24. Pidperdi B, Ling Y-H, Kroog G, Perez-Soler R. Schedule-dependent interaction between epidermal growth factor imhibitors (EGFR1) and G2/M blocking chemotherapeutic agents (G2/MC) on human NSCLC cell lines in vitro. Proc Am Soc Clin Oncol 2004; 23 (Abstr 7028).
25. Solit DB, She Y, Lobo J et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005; 11(5): 1983-1989.
26. Li T, Ling YH, Goldman ID et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007; 13(11): 3413-3422.
27. Davies AM, Ho C, Beckett L et al. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol 2009; 4(7): 862-868.
28. Furuse K, Fukuoka M, Kuba M et al. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group. Ann Oncol 1996; 7(8): 815-820.
29. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91(1): 66-72.
30. Zelek L, Barthier S, Riofrio M et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001; 92(9): 2267-2272.
31. Terzoli E, Nistico C, Fabi A et al. Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules. J Exp Clin Cancer Res 2004; 23(2): 207-213.
32. Albain K, Green SJ, Ravdin PM et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent:initial results from intergoup trial 0100 (SWOG 8814). Proc Am Soc Clin Oncol 2002; 21 (Abstr 143).
33. Burstein HJ, I Kuter, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19(10): 2722-2730.
34. Johnston S, Trudeau M, Kaufman B et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008; 26(7): 1066-1072.
35. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6(2): 117-127.
36. Xia W, Husain I, Liu L et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007; 67(3): 1170-1175.
37. O'Brien NA, Browne BC, Chow L et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010; 9(6): 1489-1502.
38. Eichhorn PJ, Gili M, Scaltrit M et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68(22): 9221-9230.